INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575694, 'Elagolix', 'Telotristat ethyl', 'Moderate', 'Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the metabolic isoenzyme and efflux transporter.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.  Alternative treatments or a dose adjustment of elagolix may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elagolix should be considered during coadministration with CYP450 3A4 and/or P-gp inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575695, 'Elbasvir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575696, 'Grazoprevir', 'Acarbose', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575697, 'Elbasvir', 'Acetohexamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575698, 'Grazoprevir', 'Acetohexamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575699, 'Elbasvir', 'Albiglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575700, 'Grazoprevir', 'Albiglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575701, 'Elbasvir', 'Alogliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575702, 'Grazoprevir', 'Alogliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575703, 'Elbasvir', 'Alpelisib', 'Moderate', 'Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter.', 'DDInter', 1767317477, 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.  Some authorities recommend coadministration of alpelisib with BCRP inhibitors be avoided whenever possible (US).', 'Excretion', 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575704, 'Grazoprevir', 'Alpelisib', 'Moderate', 'Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of adverse effects of alpelisib, which is a substrate of this efflux transporter.', 'DDInter', 1767317477, 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.  Some authorities recommend coadministration of alpelisib with BCRP inhibitors be avoided whenever possible (US).', 'Excretion', 'If coadministration with BCRP inhibitors is required, patients should be closely monitored for alpelisib-related adverse reactions, including hyperglycemia, diarrhea, rash, acute kidney injury, abdominal pain, and anemia.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575705, 'Aminoglutethimide', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575706, 'Grazoprevir', 'Aminoglutethimide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575707, 'Grazoprevir', 'Amiodarone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575708, 'Amobarbital', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575709, 'Grazoprevir', 'Amobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575710, 'Amprenavir', 'Grazoprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575711, 'Amprenavir', 'Elbasvir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575712, 'Anisindione', 'Elbasvir', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575713, 'Anisindione', 'Grazoprevir', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575714, 'Grazoprevir', 'Apalutamide', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575715, 'Grazoprevir', 'Aprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575716, 'Elbasvir', 'Armodafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575717, 'Grazoprevir', 'Armodafinil', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575718, 'Elbasvir', 'Atazanavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575719, 'Grazoprevir', 'Atorvastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575720, 'Grazoprevir', 'Bempedoic acid', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the hepatic uptake transporters.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575721, 'Elbasvir', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 1767317477, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575722, 'Grazoprevir', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat.  Berotralstat is a substrate of both P-gp and BCRP.', 'DDInter', 1767317477, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.  Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea.  Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575723, 'Elbasvir', 'Betrixaban', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter.', 'DDInter', 1767317477, 'Caution is advised when betrixaban is used with P-gp inhibitors.  Closer monitoring of the pharmacologic effects of betrixaban may be appropriate whenever a P-gp inhibitor is added to or withdrawn from therapy.  Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).  Concomitant use of betrixaban with P-gp inhibitors should be avoided in patients with severe renal impairment (CrCl<30 mL/min).', 'Excretion', 'Caution is advised when betrixaban is used with P-gp inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575724, 'Elbasvir', 'Bexarotene', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575725, 'Grazoprevir', 'Bexarotene', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575726, 'Grazoprevir', 'Bicalutamide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575727, 'Elbasvir', 'Binimetinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib.  The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', 'DDInter', 1767317477, 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.  Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575728, 'Grazoprevir', 'Binimetinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib.  The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', 'DDInter', 1767317477, 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.  Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575729, 'Grazoprevir', 'Boceprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575730, 'Elbasvir', 'Boceprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575731, 'Elbasvir', 'Bromocriptine', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575732, 'Grazoprevir', 'Bromocriptine', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575733, 'Elbasvir', 'Butabarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575734, 'Grazoprevir', 'Butabarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575735, 'Elbasvir', 'Butalbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575736, 'Grazoprevir', 'Butalbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575737, 'Elbasvir', 'Canagliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575738, 'Grazoprevir', 'Canagliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575739, 'Grazoprevir', 'Carbamazepine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575740, 'Grazoprevir', 'Ceritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575741, 'Elbasvir', 'Ceritinib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575742, 'Grazoprevir', 'Cerivastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575743, 'Grazoprevir', 'Chloramphenicol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575744, 'Elbasvir', 'Chlorpropamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575745, 'Grazoprevir', 'Chlorpropamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575746, 'Grazoprevir', 'Cimetidine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575747, 'Grazoprevir', 'Ciprofloxacin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575748, 'Grazoprevir', 'Clarithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575749, 'Elbasvir', 'Clarithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575750, 'Grazoprevir', 'Clotrimazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575751, 'Grazoprevir', 'Cobicistat', 'Major', 'Coadministration with cobicistat may increase plasma concentrations of elbasvir and grazoprevir.  The proposed mechanism is cobicistat-mediated inhibition of CYP450 3A4 and the hepatic uptake OATP1B transporter.  Elbasvir and grazoprevir are both substrates of CYP450 3A4 and grazoprevir is also a substrate of OATP1B.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with the fixed-dose cobicistat-containing antiretroviral regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or alafenamide should generally be avoided.', 'Metabolism, Distribution', 'Concomitant use of elbasvir-grazoprevir with the fixed-dose cobicistat-containing antiretroviral regimen elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or alafenamide should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575752, 'Elbasvir', 'Cobicistat', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575753, 'Grazoprevir', 'Conivaptan', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575754, 'Elbasvir', 'Conivaptan', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575755, 'Grazoprevir', 'Crizotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575756, 'Grazoprevir', 'Danazol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575757, 'Elbasvir', 'Dapagliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575758, 'Grazoprevir', 'Dapagliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575759, 'Grazoprevir', 'Darolutamide', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the hepatic uptake transporters.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575760, 'Elbasvir', 'Darunavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575761, 'Grazoprevir', 'Dasatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575762, 'Elbasvir', 'Deferasirox', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575763, 'Grazoprevir', 'Deferasirox', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575764, 'Grazoprevir', 'Delavirdine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575765, 'Elbasvir', 'Delavirdine', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575766, 'Elbasvir', 'Dicoumarol', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575767, 'Grazoprevir', 'Dicoumarol', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575768, 'Grazoprevir', 'Diltiazem', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575769, 'Grazoprevir', 'Dronedarone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575770, 'Elbasvir', 'Dulaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575771, 'Grazoprevir', 'Dulaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575772, 'Grazoprevir', 'Duvelisib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575773, 'Grazoprevir', 'Efavirenz', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575774, 'Elagolix', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575775, 'Grazoprevir', 'Elagolix', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575776, 'Empagliflozin', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575777, 'Grazoprevir', 'Empagliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575778, 'Grazoprevir', 'Enasidenib', 'Moderate', 'Based on in vitro data, coadministration with enasidenib may increase the plasma concentrations of drugs that are substrates of the transporters, organic anion transporting polypeptides (OATP) 1B1/1B3 and breast cancer resistance protein (BCRP).  The proposed mechanism is decreased clearance due to enasidenib -mediated inhibition of OATP1B1/1B3 and BCRP transporters.', 'DDInter', 1767317477, 'Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enasidenib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when enasidenib is used concurrently with medications that are substrates of OATP 1B1/1B3 and/or BCRP, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575779, 'Grazoprevir', 'Encorafenib', 'Moderate', 'Coadministration with encorafenib may theoretically increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter (OCT2), organic anion transporter (OAT1, OAT3), or organic anion transporting polypeptide (OATP1B1, OATP1B3).  The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by encorafenib.', 'DDInter', 1767317477, 'Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever encorafenib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if encorafenib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575780, 'Grazoprevir', 'Entrectinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575781, 'Grazoprevir', 'Enzalutamide', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575782, 'Ertugliflozin', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575783, 'Grazoprevir', 'Ertugliflozin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575784, 'Grazoprevir', 'Erythromycin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575785, 'Eslicarbazepine', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575786, 'Grazoprevir', 'Eslicarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575787, 'Exenatide', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575788, 'Grazoprevir', 'Exenatide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575789, 'Grazoprevir', 'Fedratinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575790, 'Felbamate', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575791, 'Grazoprevir', 'Felbamate', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575792, 'Grazoprevir', 'Fluconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575793, 'Grazoprevir', 'Fluvastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575794, 'Grazoprevir', 'Fluvoxamine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575795, 'Grazoprevir', 'Fosamprenavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575796, 'Fosamprenavir', 'Elbasvir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575797, 'Grazoprevir', 'Fosaprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575798, 'Grazoprevir', 'Fosphenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575799, 'Grazoprevir', 'Fostemsavir', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the hepatic uptake transporters.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575800, 'Glimepiride', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575801, 'Grazoprevir', 'Glimepiride', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575802, 'Glipizide', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575803, 'Grazoprevir', 'Glipizide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575804, 'Glyburide', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575805, 'Grazoprevir', 'Glyburide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575806, 'Grazoprevir', 'Goldenseal', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575807, 'Grazoprevir', 'Grepafloxacin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575808, 'Griseofulvin', 'Elbasvir', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575809, 'Grazoprevir', 'Griseofulvin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575810, 'Idelalisib', 'Grazoprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575811, 'Idelalisib', 'Elbasvir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575812, 'Imatinib', 'Grazoprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575813, 'Indinavir', 'Grazoprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575814, 'Indinavir', 'Elbasvir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575815, 'Insulin human', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575816, 'Insulin human', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575817, 'Insulin aspart (aspart)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575818, 'Insulin aspart (aspart)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575819, 'Insulin aspart (aspart protamine)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575820, 'Insulin aspart (aspart protamine)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575821, 'Insulin degludec', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575822, 'Insulin degludec', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575823, 'Insulin detemir', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575824, 'Insulin detemir', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575825, 'Insulin glargine', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575826, 'Insulin glargine', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575827, 'Insulin glulisine', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575828, 'Insulin glulisine', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575829, 'Insulin human (inhalation, rapid acting)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575830, 'Insulin human (inhalation, rapid acting)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575831, 'Insulin lispro', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575832, 'Insulin lispro', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575833, 'Insulin lispro (protamine)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575834, 'Insulin lispro (protamine)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575835, 'Insulin human (zinc)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575836, 'Insulin human (zinc)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575837, 'Insulin human (zinc extended)', 'Elbasvir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575838, 'Insulin human (zinc extended)', 'Grazoprevir', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575839, 'Isavuconazonium', 'Grazoprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575840, 'Isoniazid', 'Grazoprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575841, 'Itraconazole', 'Grazoprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575842, 'Itraconazole', 'Elbasvir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575843, 'Ivacaftor', 'Grazoprevir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575844, 'Elbasvir', 'Ivosidenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575845, 'Grazoprevir', 'Ivosidenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575846, 'Grazoprevir', 'Ketoconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575847, 'Elbasvir', 'Ketoconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575848, 'Grazoprevir', 'Larotrectinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575849, 'Grazoprevir', 'Letermovir', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575850, 'Elbasvir', 'Linagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575851, 'Grazoprevir', 'Linagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575852, 'Elbasvir', 'Liraglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575853, 'Grazoprevir', 'Liraglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575854, 'Elbasvir', 'Lixisenatide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575855, 'Grazoprevir', 'Lixisenatide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575856, 'Grazoprevir', 'Lomitapide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575857, 'Grazoprevir', 'Lonafarnib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575858, 'Elbasvir', 'Lonafarnib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575859, 'Grazoprevir', 'Lorlatinib', 'Major', 'Coadministration with moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with moderate CYP450 3A4 inducers should generally be avoided.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with moderate CYP450 3A4 inducers should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575860, 'Grazoprevir', 'Lovastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575861, 'Elbasvir', 'Lusutrombopag', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', 'DDInter', 1767317477, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.  Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Metabolism', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575862, 'Grazoprevir', 'Lusutrombopag', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', 'DDInter', 1767317477, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.  Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Metabolism', 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575863, 'Elbasvir', 'Methylphenobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575864, 'Grazoprevir', 'Methylphenobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575865, 'Elbasvir', 'Metformin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575866, 'Grazoprevir', 'Metformin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575867, 'Elbasvir', 'Metreleptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575868, 'Grazoprevir', 'Metreleptin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575869, 'Grazoprevir', 'Miconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575870, 'Elbasvir', 'Mifepristone', 'Moderate', 'Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.', 'DDInter', 1767317477, 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.  Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Metabolism', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575871, 'Grazoprevir', 'Mifepristone', 'Moderate', 'Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.', 'DDInter', 1767317477, 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.  Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Metabolism', 'Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575872, 'Elbasvir', 'Miglitol', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575873, 'Grazoprevir', 'Miglitol', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575874, 'Grazoprevir', 'Mitotane', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575875, 'Elbasvir', 'Nateglinide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575876, 'Grazoprevir', 'Nateglinide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575877, 'Grazoprevir', 'Nefazodone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575878, 'Elbasvir', 'Nefazodone', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575879, 'Grazoprevir', 'Nelfinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575880, 'Elbasvir', 'Nelfinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575881, 'Elbasvir', 'Nevirapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575882, 'Grazoprevir', 'Nevirapine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575883, 'Grazoprevir', 'Nifedipine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575884, 'Grazoprevir', 'Nilotinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575885, 'Grazoprevir', 'Osilodrostat', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575886, 'Elbasvir', 'Oxcarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575887, 'Grazoprevir', 'Oxcarbazepine', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575888, 'Grazoprevir', 'Oxycodone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of oxycodone, which is primarily metabolized by the isoenzyme.', 'DDInter', 1767317477, 'Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.  The risk of overdose may be increased following the initiation of a CYP450 3A4 inhibitor in patients already receiving oxycodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of oxycodone or development of withdrawal symptoms due to reduced plasma oxycodone levels.', 'Metabolism', 'Caution may be advisable when oxycodone is prescribed with weak CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575889, 'Elbasvir', 'Ozanimod', 'Minor', 'Breast cancer resistance protein (BCRP) inhibitors are not expected to interact with ozanimod to a clinically relevant extent.', 'DDInter', 1767317477, 'Coadministration of ozanimo with cyclosporine, a BCRP inhibitor, had no effect on the exposure to ozanimo or its major active metabolites, CC112273 and CC1084037, and therefore no adjustment is necessary.', 'Others', 'Coadministration of ozanimo with cyclosporine, a BCRP inhibitor, had no effect on the exposure to ozanimo or its major active metabolites, CC112273 and CC1084037, and therefore no adjustment is necessary.', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575890, 'Grazoprevir', 'Ozanimod', 'Minor', 'Breast cancer resistance protein (BCRP) inhibitors are not expected to interact with ozanimod to a clinically relevant extent.', 'DDInter', 1767317477, 'Coadministration of ozanimo with cyclosporine, a BCRP inhibitor, had no effect on the exposure to ozanimo or its major active metabolites, CC112273 and CC1084037, and therefore no adjustment is necessary.', 'Others', 'Coadministration of ozanimo with cyclosporine, a BCRP inhibitor, had no effect on the exposure to ozanimo or its major active metabolites, CC112273 and CC1084037, and therefore no adjustment is necessary.', NULL, NULL, 'Minor', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575891, 'Grazoprevir', 'Palbociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575892, 'Elbasvir', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575893, 'Grazoprevir', 'Pentobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575894, 'Grazoprevir', 'Pexidartinib', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the hepatic uptake transporters.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575895, 'Grazoprevir', 'Phenobarbital', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575896, 'Elbasvir', 'Phenylbutazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575897, 'Grazoprevir', 'Phenylbutazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575898, 'Grazoprevir', 'Phenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575899, 'Elbasvir', 'Pioglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575900, 'Grazoprevir', 'Pioglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575901, 'Grazoprevir', 'Posaconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575902, 'Elbasvir', 'Posaconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575903, 'Grazoprevir', 'Pralsetinib', 'Moderate', 'Coadministration with pralsetinib may increase the plasma concentrations of drugs that are P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, organic anion transporter 1 (OAT1), multidrug and toxin extrusion 1 (MATE1), and/or MATE2-K substrates.', 'DDInter', 1767317477, 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with substrates of these transporters for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.', 'Metabolism, Excretion', 'Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OATP1B1, OATP1B3, OAT1, MATE1, and/or MATE2-K, particularly sensitive substrates or those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575904, 'Elbasvir', 'Pramlintide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575905, 'Grazoprevir', 'Pramlintide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575906, 'Grazoprevir', 'Primidone', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575907, 'Grazoprevir', 'Ranolazine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575908, 'Elbasvir', 'Repaglinide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575909, 'Grazoprevir', 'Repaglinide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575910, 'Grazoprevir', 'Ribociclib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575911, 'Grazoprevir', 'Rifabutin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575912, 'Grazoprevir', 'Rifampicin', 'Major', 'The plasma concentrations of grazoprevir may increase significantly during acute coadministration with rifampin, but decreases after chronic coadministration.  The proposed mechanism is rifampin inhibition of organic anion transporting polypeptide (OATP) 1B1-mediated hepatic uptake of grazoprevir initially, followed by induction of CYP450 3A4-mediated metabolism after multiple-dosing.', 'DDInter', 1767317477, 'MANAGEMENT Concomitant use of elbasvir-grazoprevir with rifampin is considered contraindicated.', 'Metabolism, Distribution', 'MANAGEMENT Concomitant use of elbasvir-grazoprevir with rifampin is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575913, 'Grazoprevir', 'Rifapentine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575914, 'Elbasvir', 'Rimegepant', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant.  The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.', 'DDInter', 1767317477, 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', 'Metabolism', 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575915, 'Grazoprevir', 'Rimegepant', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant.  The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.', 'DDInter', 1767317477, 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', 'Metabolism', 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575916, 'Elbasvir', 'Ritonavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575917, 'Elbasvir', 'Rosiglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575918, 'Grazoprevir', 'Rosiglitazone', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575919, 'Grazoprevir', 'Rosuvastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575920, 'Grazoprevir', 'Rucaparib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575921, 'Elbasvir', 'Rufinamide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575922, 'Grazoprevir', 'Rufinamide', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575923, 'Elbasvir', 'Saquinavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575924, 'Elbasvir', 'Saxagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575925, 'Grazoprevir', 'Saxagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575926, 'Elbasvir', 'Secobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575927, 'Grazoprevir', 'Secobarbital', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575928, 'Grazoprevir', 'Selinexor', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the hepatic uptake transporters.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with OATP 1B1 or 1B3 inhibitors is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575929, 'Grazoprevir', 'Selpercatinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575930, 'Elbasvir', 'Semaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575931, 'Grazoprevir', 'Semaglutide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575932, 'Grazoprevir', 'Simvastatin', 'Major', 'Coadministration with elbasvir-grazoprevir may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the CYP450 3A4 isoenzyme and/or breast cancer resistance protein (BCRP) transporter.  Grazoprevir is reported to be a relatively weak inhibitor of CYP450 3A4 in vivo, and both elbasvir and grazoprevir are inhibitors of BCRP at the intestinal level in humans.', 'DDInter', 1767317477, 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.  Atorvastatin dosage should not exceed 20 mg/day and rosuvastatin dosage should not exceed 10 mg/day according to the product labeling for elbasvir-grazoprevir.  The lowest effective dose of fluvastatin, lovastatin, or simvastatin should be used; some authorities recommend a maximum daily dose of 20 mg of these statins.  In contrast, pitavastatin and pravastatin do not have clinically relevant interactions with elbasvir-grazoprevir, and no dosage adjustments are necessary.  All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine.  Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Caution is advised when statins such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, and simvastatin are prescribed with elbasvir-grazoprevir.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575933, 'Elbasvir', 'Sitagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575934, 'Grazoprevir', 'Sitagliptin', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575935, 'Elbasvir', 'Somapacitan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575936, 'Grazoprevir', 'Somapacitan', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575937, 'Elbasvir', 'Somatrem', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575938, 'Grazoprevir', 'Somatrem', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575939, 'Elbasvir', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575940, 'Grazoprevir', 'Somatotropin', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575941, 'Grazoprevir', 'St. John''s Wort', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', 'Metabolism', 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of elbasvir-grazoprevir with efavirenz or potent CYP450 3A4 inducers is considered contraindicated.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575942, 'Grazoprevir', 'Stiripentol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575943, 'Elbasvir', 'Sulfinpyrazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575944, 'Grazoprevir', 'Sulfinpyrazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575945, 'Grazoprevir', 'Sunitinib', 'Moderate', 'Coadministration of sunitinib with elbasvir-grazoprevir may increase the plasma concentrations and the risk of adverse effects of sunitinib.  The proposed mechanism by which elbasvir-grazoprevir increases sunitinib exposure has not been clearly delineated, but may involve inhibition of intestinal breast cancer resistance protein (BCRP).', 'DDInter', 1767317477, 'Although the interaction has not been studied, caution is advised if sunitinib and elbasvir-grazoprevir are used in combination.  Dose adjustment of sunitinib as well as clinical and laboratory monitoring of sunitinib should be considered whenever elbasvir-grazoprevir is added to or withdrawn from therapy.  During concomitant treatment, patients should be monitored for signs and symptoms of sunitinib toxicity such as diarrhea, hypertension, and/or neutropenia.', 'Absorption', 'Although the interaction has not been studied, caution is advised if sunitinib and elbasvir-grazoprevir are used in combination.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575946, 'Grazoprevir', 'Suvorexant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575947, 'Grazoprevir', 'Tacrolimus', 'Moderate', 'Coadministration with elbasvir-grazoprevir may increase the blood concentrations of tacrolimus.  The proposed mechanism is inhibition of the CYP450 3A4-mediated metabolism of tacrolimus by grazoprevir, a weak inhibitor of the isoenzyme.', 'DDInter', 1767317477, 'Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of tacrolimus, caution is advised if the drug is used in combination with elbasvir-grazoprevir.  Renal function and tacrolimus blood levels should be monitored more closely whenever elbasvir-grazoprevir is added to or discontinued from therapy, and the tacrolimus dosage adjusted as necessary.  Patients should be advised to contact their doctor if they experience potential signs and symptoms of tacrolimus toxicity such as fever, infection, diarrhea, tremor, headache, fatigue, lethargy, and changes in motor function, mental status, or sensory function.', 'Metabolism', 'Given the narrow therapeutic index and the large interindividual variability in the pharmacokinetics of tacrolimus, caution is advised if the drug is used in combination with elbasvir-grazoprevir.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575948, 'Elbasvir', 'Talazoparib', 'Moderate', 'Coadministration with sparsentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2B6, 2C9, and 2C19 isoenzymes.  The proposed mechanism is increased clearance due to sparsentan-mediated induction of CYP450 2B6, 2C9, and 2C19.', 'DDInter', 1767317477, 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.  However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.', 'Metabolism', 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575949, 'Grazoprevir', 'Talazoparib', 'Moderate', 'Coadministration with sparsentan may decrease the plasma concentrations of drugs that are substrates of the CYP450 2B6, 2C9, and 2C19 isoenzymes.  The proposed mechanism is increased clearance due to sparsentan-mediated induction of CYP450 2B6, 2C9, and 2C19.', 'DDInter', 1767317477, 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.  However, patients should be closely monitored for adverse effects such as myelosuppression and myelodysplastic syndrome/acute myeloid leukemia, and dosage adjustments made or treatment withheld as needed in accordance with the product labeling.', 'Metabolism', 'No initial dosage adjustment is recommended by the manufacturer when talazoparib is coadministered with inhibitors of BCRP and/or P-gp other than amiodarone, carvedilol, clarithromycin, itraconazole, or verapamil.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575950, 'Elbasvir', 'Telaprevir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575951, 'Elbasvir', 'Telithromycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575952, 'Grazoprevir', 'Ticagrelor', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575953, 'Elbasvir', 'Tipranavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575954, 'Elbasvir', 'Tolazamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575955, 'Grazoprevir', 'Tolazamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575956, 'Elbasvir', 'Tolbutamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575957, 'Grazoprevir', 'Tolbutamide', 'Moderate', 'Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered blood glucose control.  Serious symptomatic hypoglycemia has been reported in diabetic patients in postmarketing case reports and published epidemiological studies.', 'DDInter', 1767317477, 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.  The patient as well as the healthcare providers in charge of diabetic care should be apprised of the risk of hypoglycemia.  Patients should be aware of the potential signs and symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia.  For antidiabetic medications that are not glucose-dependent, reduction in the dosage should be considered to mitigate the risk of hypoglycemia.', 'Synergism', 'Blood glucose should be closely monitored during treatment of HCV with DAAs, particularly during the first 3 months, and appropriate changes made to the antidiabetic drug regimen as needed.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575958, 'Elbasvir', 'Troglitazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575959, 'Grazoprevir', 'Troglitazone', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575960, 'Grazoprevir', 'Troleandomycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575961, 'Elbasvir', 'Troleandomycin', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575962, 'Grazoprevir', 'Tucatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575963, 'Elbasvir', 'Tucatinib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575964, 'Elbasvir', 'Ubrogepant', 'Moderate', 'Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.', 'DDInter', 1767317477, 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.  If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.', 'Metabolism', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575965, 'Grazoprevir', 'Ubrogepant', 'Moderate', 'Coadministration with breast cancer resistance protein (BCRP) and/or P-glycoprotein (P-gp) only inhibitors may increase the exposure of ubrogepant, which is a substrate of these transporters.', 'DDInter', 1767317477, 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.  If needed, a second 50 mg dose of ubrogepant may be administered at least 2 hours after the initial dose.', 'Metabolism', 'The manufacturer recommends an initial ubrogepant dose of 50 mg when coadministered with BCRP and/or P-gp only inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575966, 'Elbasvir', 'Vemurafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575967, 'Grazoprevir', 'Vemurafenib', 'Moderate', 'Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of elbasvir and grazoprevir, both of which are substrates of the isoenzyme.', 'DDInter', 1767317477, 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.  Alternative treatments may be required if an interaction is suspected.', 'Metabolism', 'The potential for diminished pharmacologic effects of elbasvir-grazoprevir should be considered during coadministration with CYP450 3A4 inducers.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575968, 'Grazoprevir', 'Verapamil', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575969, 'Grazoprevir', 'Voriconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir-grazoprevir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Major', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575970, 'Elbasvir', 'Voriconazole', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elbasvir, which is a substrate of the isoenzyme', 'DDInter', 1767317477, 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Concomitant use of elbasvir with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575971, 'Grazoprevir', 'Voxelotor', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575972, 'Elbasvir', 'Warfarin', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575973, 'Grazoprevir', 'Warfarin', 'Moderate', 'Liver function changes due to treatment with direct-acting HCV antiviral agents may affect the therapeutic efficacy of vitamin K antagonists.  The mechanism may involve potential pharmacokinetic changes for some vitamin K antagonists due to altered metabolism, or patients may exhibit alterations in hepatic synthesis of vitamin K-dependent coagulation factors and clearance of activated factors that could impact response to vitamin K antagonists.', 'DDInter', 1767317477, 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', 'Others', 'The INR should be monitored more closely following initiation or discontinuation of a direct-acting HCV antiviral agent, and the dosage of vitamin K antagonist adjusted if necessary.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575974, 'Grazoprevir', 'Zafirlukast', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of grazoprevir, which is a substrate of the isoenzyme.', 'DDInter', 1767317477, 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.  Patients should be monitored for increased adverse effects such as nausea, vomiting, and ALT elevations.', 'Metabolism', 'Caution is advised if elbasvir-grazoprevir is prescribed in combination with CYP450 3A4 inhibitors.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575975, 'Elexacaftor', 'Ambrisentan', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575976, 'Elexacaftor', 'Atorvastatin', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575977, 'Elexacaftor', 'Bosentan', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575978, 'Ivacaftor', 'Brentuximab vedotin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin.  MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter.', 'DDInter', 1767317477, 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic.  Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.', 'Metabolism', 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575979, 'Elexacaftor', 'Cerivastatin', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575980, 'Elexacaftor', 'Drospirenone', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575981, 'Empagliflozin', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575982, 'Ethinylestradiol', 'Elexacaftor', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575983, 'Etonogestrel', 'Elexacaftor', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575984, 'Ezetimibe', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575985, 'Fexofenadine', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575986, 'Fluvastatin', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575987, 'Glyburide', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575988, 'Irinotecan', 'Elexacaftor', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575989, 'Elexacaftor', 'Levonorgestrel', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575990, 'Elexacaftor', 'Lovastatin', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575991, 'Elexacaftor', 'Medroxyprogesterone acetate', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575992, 'Elexacaftor', 'Methotrexate', 'Moderate', 'Coadministration with elexacaftor may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptides (OATP) 1B1 and 1B3.  The proposed mechanism, based on in vitro data, involves decreased metabolic clearance due to inhibition of OATP 1B1- and 1B3-mediated hepatic uptake by elexacaftor and its metabolite.', 'DDInter', 1767317477, 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever elexacaftor is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when elexacaftor is used concurrently with drugs that are known OATP 1B1 and 1B3 substrates, particularly those with a narrow therapeutic range.', NULL, NULL, 'Moderate', 'pharmacodynamic');
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, updated_at, management_text, mechanism_text, recommendation, arabic_recommendation, arabic_effect, risk_level, type) VALUES (1575993, 'Elexacaftor', 'Norethisterone', 'Moderate', 'Concomitant use of hormonal contraceptives and ivacaftor/tezacaftor/elexacaftor (IVA/TEZ/ELX) may increase the risk for rash events.', 'DDInter', 1767317477, 'Monitor for rash in patients taking both medications.  Consider interrupting IVA/TEZ/ELX and hormonal contraceptives in patients who develop rash.  Once the rash clears, IVA/TEZ/ELX may be restarted without the hormonal contraceptives.  If rash does not recur, resumption of hormonal contraceptives can be considered.', 'Others', 'Monitor for rash in patients taking both medications.', NULL, NULL, 'Moderate', 'pharmacodynamic');
